| Literature DB >> 34193869 |
Donata Hoffmann1, Björn Corleis2, Susanne Rauch3, Nicole Roth3, Janine Mühe3, Nico Joel Halwe1, Lorenz Ulrich1, Charlie Fricke2, Jacob Schön1, Anna Kraft1, Angele Breithaupt4, Kerstin Wernike1, Anna Michelitsch1, Franziska Sick1, Claudia Wylezich1, Bernd Hoffmann1, Moritz Thran3, Andreas Thess3, Stefan O Mueller3, Thomas C Mettenleiter5, Benjamin Petsch3, Anca Dorhoi6, Martin Beer7.
Abstract
The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34193869 DOI： 10.1038/s41467-021-24339-7
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919